New drug shows promise for Tough-to-Treat throat cancer
NCT ID NCT03848286
First seen May 08, 2026 · Last updated Jun 22, 2026 · Updated 10 times
Summary
This phase 2 trial tested a drug called KL-A167 in 153 adults with recurrent or metastatic nasopharyngeal carcinoma (a type of throat cancer). Participants received the drug by IV every two weeks. The main goal was to see how many patients' tumors shrank or disappeared. The study is complete, and results will help determine if this drug is safe and effective enough for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KL-A167 (a drug given by IV every 2 weeks)
What this could lead to
If it works, this could offer a new treatment option for people with advanced nasopharyngeal cancer that has come back or spread.
What could go wrong
This is a mid-stage trial with no control group, so results are preliminary. The drug may not work for everyone and could cause side effects like immune-related reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.